



MEDIA ALERT: Canadian Webinar Series Connects Contrast Management Evidence with Real-World Myopia Control for Children

SightGlass Vision will continue its Canadian educational webinar series on contrast management for myopia control with a new session drawing on experience from pediatric practice. On Oct. 7 at 7 p.m. ET (4 p.m. PT), the company will host *“From Contrast Management to Myopia Control: Insights and Best Practices.”* The one-hour session will explore patient cases and firsthand experience using contrast management to slow myopia progression in children.

Canadian eye care professionals interested in attending the webinar can [register here](#).

Kimberley Nguyen, OD, FOVDR, of Vaughan Vision Centre in Vaughan, Ontario, will share her experience prescribing DOT® spectacle lenses, available in Canada as MiSight® Spectacle Lenses powered by Diffusion Optics Technology™. Using examples from her own practice, she will discuss cases where young children with progressing myopia remained stable for several years while wearing the lenses, as well as children who continued to progress with other myopia control approaches and experienced slower progression after switching to contrast management.

“They’re actually my go-to lens, especially for younger children,” said Dr. Nguyen. “I’ve had patients with no progression at all for more than three years. This is the only treatment option in Canada that works just by managing contrast, and because it’s a different mechanism of action, I feel there needs to be more awareness of it among eye care professionals practicing myopia management.”

The webinar will also feature Fabio Carta, Dip. Optom, FBCLA, Director of Professional Affairs at SightGlass Vision, who will take a deep dive into the evidence base supporting contrast management for myopia control and the technology behind the lenses. MiSight® Spectacle Lenses powered by Diffusion Optics Technology™ are designed to provide contrast-based myopia control while preserving excellent visual acuity. Other optical interventions that use defocus power may cause refractive blur when the patient views through the treatment zone.^{[1],[2]} Research has found that the lenses saved more than 1D of progression on average after two years in Chinese children aged 6 to 10.^{[3]*}

The session will close with a Q&A for attendees. Another webinar in the series is scheduled for Oct. 21, with details to come. For more information on the Oct. 7 webinar, [visit the registration page](#).

###

**Prescribed DOT lens wear time was 10 hours per day. LS Mean progression difference of 1.01D between test and control groups.*

About SightGlass Vision

SightGlass Vision™ develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on landmark discoveries surrounding myopia progression. DOT™ spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina. DOT™ lenses provide myopia control through contrast management and have proven results from Gold-standard clinical trials in North America and China. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.

MiSight® Spectacle Lenses powered by Diffusion Optics Technology™ are not available for sale in the U.S.

Diffusion Optics Technology and DOT are trademarks of SightGlass Vision, Inc. © 2026 SightGlass Vision, Inc. All Rights Reserved.

^[1] Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023 Nov;107(11):1709-1715. doi: 10.1136/bjo-2021-321005. Epub 2022 Sep 1.

^[2] Desiato et al. The Impact of Myopia Control Spectacle Lens Designs on Visual Function. Ophthalmic Physiol. Opt. 2026;46, 49–59 <https://doi.org/10.1007/s44402-026-00026-2>.

^[3] SGV data on file 2026. Control of myopia using contrast modulation spectacle lenses in a Chinese population (n = 172 (6-10 years: 117), 5 sites in China). Overall patient population aged 6–13 years. The clinical trial was designed to compare DOT lenses with conventional single vision lenses to evaluate their continued safety and efficacy in Chinese children.